ALS Untangled does not recommend CuATSM for ALS outside clinical trials
Original source
Copper ATSM (opens in a new tab)Related topics
ALS Untangled advises against using copper ATSM (CuATSM) for amyotrophic lateral sclerosis (ALS) until clinical trials clarify its safety, dose and effectiveness. The review says CuATSM has shown promising mechanisms and results in mutant SOD1 ALS models, but reports of benefit from people with ALS are few and uncertain.
Why this matters
This applies to people considering CuATSM, including those with SOD1 mutations. The evidence described is mainly preclinical, and the review does not establish a treatment benefit in people. It also says repeated-dose safety, the best daily dose and effectiveness in people with and without SOD1 mutations remain unclear.
Limitations and context
This is a 2017 expert review from ALS Untangled, not a clinical trial or primary research report. The human evidence described consists of a small number of patient reports with uncertain clinical significance. Further clinical trials would need to establish dosing, safety and effectiveness; the review also notes that CuATSM appears expensive.